Alnylam Pharmaceuticals
Yahoo Finance • 11 days ago
US Stock Market Today: S&P 500 Futures Steady As Traders Weigh Global Factory Strength
The Morning Bull - US Market Morning Update Friday, Oct, 2 2026 US stock futures are mixed in early trade, with E-mini S&P 500 contracts roughly flat while Nasdaq-100 futures edge higher. Investors are weighing strong factory readings fro... Full story
Yahoo Finance • 14 days ago
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Dr. Rajeev Mohan sitting in his office, in conversation with Pete and Kari Shaw. – Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM... Full story
Yahoo Finance • 21 days ago
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Alzheimer's Disease International ("ADI") observes Sept. 21 as World Alzheimer's Day, while September is marked as World Alzheimer's Month to raise awareness about Alzheimer's disease (AD) and other forms of dementia. The 2026 campaign — T... Full story
Yahoo Finance • 28 days ago
Slate Medicines Names Kenneth Koblan as Chief Scientific Officer
By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief... Full story
Yahoo Finance • 28 days ago
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
Company Logo Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate Adoption Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Op... Full story
Yahoo Finance • 28 days ago
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
There's no way to spin Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock performance in 2026 in a positive light. It's been downright ugly. Alnylam's share price plunged more than 50% year-to-date earlier this summer and remains around 40% bel... Full story
Yahoo Finance • last month
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for TG Therapeutics (TGTX). Shares have added about 15.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings rele... Full story
Yahoo Finance • last month
Ten healthcare stocks leading in year-over-year CapEx growth
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthca... Full story
Yahoo Finance • last month
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these con... Full story
Yahoo Finance • last month
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case
[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) on Sunday presented new analyses supporting the use of Amvuttra across a range of patients wi... Full story
Yahoo Finance • last month
Alnylam drops as AstraZeneca posts full trial results for failed heart drug
[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) on Friday released full data from a failed Phase 3 trial for its RNA-targeting silencer Wainua, developed w... Full story
Yahoo Finance • 2 months ago
Alnylam stock drops on rival heart trial: Why analysts see core business safe
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell o... Full story
Yahoo Finance • 2 months ago
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Photo by geralt on Pixabay Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue. Moderna (MRNA) has returned about 486% over the trailing twelve months... Full story
Yahoo Finance • 2 months ago
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BridgeBio Pharma BBIO entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-t... Full story
Yahoo Finance • 2 months ago
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BridgeBio Pharma BBIO is entering a pivotal commercial stretch. Attruby is scaling quickly, while three late-stage candidates could widen the company's revenue base over the next year. The trade-off is a demanding valuation alongside cont... Full story
Yahoo Finance • 2 months ago
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
BridgeBio Pharma BBIO shares have gained 24% in the past three months, far ahead of the S&P 500's 0.7% rise over the same period. The move leaves investors weighing whether improving commercial and pipeline momentum can support further gai... Full story
Yahoo Finance • 2 months ago
Alnylam Pharmaceuticals (ALNY) Heads To ESC With New Data, Is It A Bargain?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Alnylam Pharmaceuticals (ALNY) has drawn market attention after announcing plans to present new clinical and real-worl... Full story
Yahoo Finance • 2 months ago
Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks
The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contribut... Full story
Yahoo Finance • 2 months ago
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Alnylam (ALNY) To Contact Them Directly To Discuss Their Options If you purchased or acquired stock in Alnylam... Full story
Yahoo Finance • 2 months ago
Securities Fraud Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ... Full story